Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
endometrial cancer
Pharma
Karyopharm reports Xpovio miss, FDA filing in separate cancers
Reporting a new miss in one cancer indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another.
Fraiser Kansteiner
Jul 31, 2026 10:00am
Merck touts Keytruda front-line win in endometrial cancer subtype
Jul 15, 2026 3:33pm
BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Jul 9, 2026 2:17pm
In endometrial cancer, Merck and Kelun score with sac-TMT
May 18, 2026 11:21am
Merck's Keytruda turns in mixed results in gynecological cancers
Sep 13, 2024 6:05pm
GSK blows Jemperli marching brass against Keytruda with new nod
Aug 1, 2024 3:00pm
